Experimental anticancer drug shows promise!
Two FDA-approved drugs, nintedanib and pirfenidone, are currently used to slow IPF disease progression, but they have side effects and do not completely relieve symptoms or cure the disease. Better drugs are needed, the researchers said.
In the new study, the researchers identified saracatinib as a candidate for treating IPF by using computational predictions that screened drug candidates for anti-fibrotic effects. The researchers then exposed the drug to human lung cells in culture and found that it could reverse the disease signature of IPF.
